期刊文献+

乙型肝炎前S1、S2抗原与HBV-DNA的相关性分析 被引量:3

Relationship between hepatitis B virus former S1 antigen,former S2 antigen,and HBVDNA,and their clinical significance
下载PDF
导出
摘要 目的对比分析乙型肝炎(乙肝)前S1、S2抗原和HBV-DNA的相关性,探讨乙肝前S1、S2抗原的临床应用价值。方法随机选取乙肝患者420例,采用ELISA法对前S1、前S2抗原进行检测,采用荧光定量PCR对HBV-DNA进行检测,从血清学标志类型、HBV-DNA载量和HBV感染类型角度对HBV-DNA和前S1、S2抗原检测结果进行分析。结果乙肝大三阳患者乙肝前S1、S2抗原和HBV-DNA阳性率分别为98.48%、95.45%、100.0%;小三阳患者乙肝前S1、S2抗原和HBVDNA阳性率分别为53.25%、45.45%、46.75%。HBs Ag(+)HBc Ab(+)患者乙肝前S1、S2抗原和HBV-DNA阳性率分别为53.75%、43.28%、44.78%。在高HBV-DNA载量组中乙肝前S1、S2抗原检出率较高。结论乙肝前S1、S2抗原与HBV-DNA有较好的相关性,可作为反映病毒感染与复制的指标。 Objective To study the relationship between HBV Pre-S1 antigen,HBV Pre-S2 antigen and HBV-DNA and inves-tigate the clinical significance of the hepatitis B virus ( HBV) .Methods The markers Pre-S1 antigen, Pre-S2 antigen were deter-mined by ELISA and HBV-DNA by the fluorescence quantitative PCR in 420 patients with HBV collected from September 2013 to May 2014.HBV, Pre-S1 antigen and Pre-S2 antigen results were analysed in different aspects, such as serum indices, HBV-DNA amounts and HBV-DNA infection types.Results In “big sanyang” patients the positive rates of Pre-S1, S2 antigen and HBV-DNA were 98.48%, 95.45%, 100%,respectively.In“small Sanyang” patients, the positive rates of Pre-S1, S2 antigen and HBV-DNA were 53.25%, 45.45%, 46.75%,respectively.In HBsAg+HBcAb+patients the positive rate of Pre-S1, S2 antigen and HBV-DNA were 53.75%, 43.28%, 44.78%,respectively.And the detection rates of HBV Pre-S1 antigen, HBV Pre-S2 antigen were higher in pa-tients infected with high level of HBV-DNA.Conclusions There is a good correlation between HBV Pre-S1 antigen, HBV Pre-S2 an-tigen and HBV-DNA, which can reflect virus infection and replication.
出处 《武警医学》 CAS 2015年第6期600-602,共3页 Medical Journal of the Chinese People's Armed Police Force
关键词 前S1抗原 前S2抗原 HBV-DNA Pre-S1Ag Pre-S2Ag HBV-DNA
  • 相关文献

参考文献12

二级参考文献40

  • 1郑昕,杨东亮.乙型肝炎病毒S基因变异研究进展[J].中华肝脏病杂志,2001,9(S1):120-121. 被引量:11
  • 2董运启.乙型肝炎病毒前S1蛋白检测的临床价值[J].国际检验医学杂志,2012,33(S1):19-21. 被引量:2
  • 3彭炎强,史伟,叶智明,梁馨苓,何朝生,章斌,王文健,梁永正.检测血清胱抑素C诊断急性肾衰竭的研究[J].新医学,2005,36(10):570-572. 被引量:23
  • 4俸家富,陈婷梅,涂植光.感染HBV或HCV的肝病患者血清半胱氨酸蛋白酶抑制剂C的改变[J].中华检验医学杂志,2006,29(11):987-990. 被引量:28
  • 5D'Mello F, Partidos CD, Steward MW, et al. Definition of the primary structure of hepatitis B virus(HBV) Pre-S hepatocyte binding domain using random peptide libraries [ J ]. Virology, 1997,237 ( 2 ) : 319-326.
  • 6Takeuchi M, Fukuda Y, Nakano I, et al. Elevation of ser-um cystatin C concentra - tions in patients with chronic liver disease [ J ]. Eur J Castroenterol Hepatol, 2001,12 (8) :951 -955.
  • 7Filer G, Prien F, Vollmer,et al. Diagnostic sensitivity of serum cys - tatin for in paired giomeruiar filtration rat [J]. Pediatri Nephro, 1999, 13 (6):501-505.
  • 8李波,苏松,杨中能,等.血清胱抑素C对肝硬化患者肾功能损害的早期诊断价值研究[J].中华肝脏外科杂志,2010,16(12):922-924.
  • 9Ueno T, Tamaki S, Sugawara H, et al. Significance of serum tissue inhibitor of metalloproteinases - 1 in various liver diseases[ J]. J Hepatol, 1996,24 : 177 - 184.
  • 10Filler G, Bokcnkamp A Hofmanm W, et al. Cyststin C as a marker of GFR - history indications and future re- search[ J]. Clin Biochem,2005,38 ( 1 ) : 1 - 8.

共引文献51

同被引文献36

  • 1中华医学会肝病学分会 中华医学会感染病学分会.慢性乙型肝炎防治指南.中华肝脏病杂志,2010,19(1):3760-3769.
  • 2European, Association. For The Study of The Liver. EA-SL clinical practice guidelines: management of chronic hepatitis B virus infection[ J ]. J Hepatol,2012,57 (1) : 167-185.
  • 3Hadziyannis S J,Tassopoulos N C,Heathcote E J,et al. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitisB for up to 5years [ J]. Gastroenterology, 2006, 131 (9) : 1743-1751.
  • 4Marcellin P, Chang T L, Lim S G, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B [ J ]. Hepatology, 2008,48 ( 12 ) : 750-758.
  • 5Minde Z, Yimin M, Ouangbi Y, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B [ J ]. Liver Int, 2012,32(6) :137-146.
  • 6WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection[ EB/OL]. [2015-03-12]. http://www, who. int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/.
  • 7Nguyen M H, Trinh H N, Do S T, et al. Complete viral suppression (CVS) rates at year 2 in adefovir-experienced chronic hepatitis B (CHB) patients who were switched to entecavir monotherapy: a muhicenter study [ J ]. Hepatology ,2011,54 ( 4 ) : S73.
  • 8Hu C Y, Liu Y M, Liu Y, et al. Pharmacokinetics and tolerability of tenofovir disoproxil fumarate 300 mg once daily: an open-label, single healthy chinese subjects [ J ] and mu].tiple-dose study in Clin Ther, 2013,35 ( 12 ) :1884-1889.
  • 9Gordon S C, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load [J]. nepatology, 2013,58(2):505-513.
  • 10Liaw Y F, Sheen I S, Lee C M, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and ente- cavir in patients with decompensated chronic hepatitis B liver disease [ J ]. Hepatology, 2011,53 ( 1 ) :62-72.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部